Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 August 2020 | Story Xolisa Mnukwa
SRC election term extended

SRC elections 2020/21 were due to take place before the end of August 2020 as prescribed by the ISRC constitution. However, owing to the COVID-19 pandemic, and the consequent lockdown regulations and extension of the UFS 2020 academic year, the current SRC term will be extended until March 2021.

The decision to extend the term of the SRC was taken by the Rectorate following a recommendation made by the Division of Student Affairs (DSA), after consultation with
the ISRC. 

The consultation process with the ISRC produced three options:
  • Proceed with SRC elections in August 2020;
  • Extend the current SRC term to align with the extended 2020 academic year; or
  • Elect a Transitional Student Council (TSC) from September 2020 to March 2021.
In view of the above, and considering current conditions amid the coronavirus pandemic,
online SRC elections are scheduled for March 2021. 

This extension implies that the terms of all the sub-structures of the ISRC will be extended accordingly.

This communication serves as official notice to the Student Body about the extension of the
2019/2020 ISRC term and all its sub-structures as per the prescripts of the ISRC Constitution.

The DSA, with particular reference to the Student Governance Office (SGO), remains
committed to engaging with all parties of legitimate interest about matters arising from,
related to, and/or about SRC elections in all its permutations. 

Should you have any questions or comments, please feel free to contact the SGO:
Coordinator: Kamogelo Dithebe (DithebeKS@ufs.ac.za)
Faculty Coordinator: (MunzheleleD@ufs.ac.za)
Administrator: Rethabile Motseki (MotsekiR@ufs.ac.za)

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept